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Abstract
The prevalence of hepatic cirrhosis in Europe and 
the United States, currently 250 patients per 100000 
inhabitants, is steadily increasing. Thus, we observe a 
significant increase in patients with cirrhosis and portal 
hypertension needing liver resections for primary or 
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metastatic lesions. However, extended liver resections 
in patients with underlying hepatic cirrhosis and portal 
hypertension still represent a medical challenge in 
regard to perioperative morbidity, surgical management 
and postoperative outcome. The Barcelona Clinic Liver 
Cancer classification recommends to restrict curative 
liver resections for hepatocellular carcinoma in cirrhotic 
patients to early tumor stages in patients with Child A 
cirrhosis not showing portal hypertension. However, 
during the last two decades, relevant improvements 
in preoperative diagnostic, perioperative hepatologic 
and intensive care management as well as in surgical 
techniques during hepatic resections have rendered 
even extended liver resections in higher-degree 
cirrhotic patients with portal hypertension possible. 
However, there are few standard indications for hepatic 
resections in cirrhotic patients and risk stratifications 
have to be performed in an interdisciplinary setting for 
each individual patient. We here review the indications, 
the preoperative risk-stratifications, the morbidity and 
the mortality of extended resections for primary and 
metastatic lesions in cirrhotic livers. Furthermore, 
we provide a review of literature on perioperative 
management in cirrhotic patients needing extrahepatic 
abdominal surgery and an overview of surgical options 
in the treatment of hepatic cirrhosis.
Key words: Liver resection; Hepatocellular carcinoma; 
Liver metastases; Portal hypertension; Cholangiocellular 
carcinoma; Cirrhosis
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Core tip: Liver resections in patients with underlying 
hepatic cirrhosis and portal hypertension still represent 
a medical challenge with regard to perioperative 
morbidity, surgical management and postoperative 
outcome. However, the increasing incidence of 
liver cirrhosis on the one hand, and the ongoing 
improvements in surgical technique and perioperative 
management on the other hand have up until today 
rendered even extended hepatic resections in these 
individual parameter results in a continuous increase 
in MELD score, risk discrimination of individual pa­
tients is more accurate than using the CPT score[6,7]. 
However, neither the CPT­ nor the MELD­score were 
originally created for surgical settings. While the CPT 
classification was developed to estimate the liver­
specific overall survival of cirrhotic patients, the MELD-
score was developed for estimating the mortality 
after TIPS (transjugular portosystemic stent shunt) 
­placement[4,5]. A main drawback in surgical risk 
stratification is that both scoring systems do not 
include features of portal hypertension except for 
ascites in the CPT classification. 
Portal hypertension is defined as an increased 
pressure gradient between portal vein and hepatic 
veins [= portal­pressure gradient (PPG) also called the 
porto­caval gradient/porto­systemic gradient]. The 
hepatic venous pressure gradient (HVPG) is an indirect 
measurement of the real PPG, which allows obviating 
the risks linked with the direct puncture of the portal 
vein[8]. Under physiological conditions, the HVPG 
is 1 to 5 mmHg. Subclinical portal hypertension is 
defined as a HVPG of 5 to 9 mmHg. Clinically relevant 
portal hypertension shows a HVPG of ≥ 10 mmHg. 
Reasons for portal hypertension are shown in Table 2. 
In Western countries, hepatic cirrhosis accounts for > 
90% of cases of portal hypertension.
Gold standard for assessing the HVPG is the angio­
invasive measurement of the free hepatic venous 
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Table 1  Causes of liver cirrhosis
Alcoholic liver disease
Chronic viral hepatitis (hepatitis B and C)
Non-alcoholic fatty liver disease
Primary and secondary biliary cirrhosis
Primary sclerosing cholangitis
Hemochromatosis
Autoimmune hepatitis
Wilson’s disease
α1-Antitrypsin deficiency
Celiac disease
Right-sided heart failure
Granulomatous liver disease
Congenital malformation syndromes
Table 2  Most frequent causes of portal hypertension
Prehepatic etiology of portal hypertension
   Portal vein thrombosis
   External portal vein compression
Intrahepatic etiology of portal hypertension
   Hepatic cirrhosis (of any origin)
   Congenital hepatic fibrosis
   Schistosomiasis
   Idiopathic non-cirrhotic portal hypertension
Posthepatic etiology of portal hypertension
   Budd-Chiari’s syndrome
   Sinusoidal obstruction syndrome
   Cirrhose cardiaque
patients possible. Especially in primary and metastatic 
liver malignancies, surgery often presents the only 
curative approach and thus potential short- and long-
term benefits and risks have to be evaluated carefully 
and interdisciplinary from a surgical, oncological and 
hepatologist point of view. 
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INTRODUCTION
Liver cirrhosis and portal hypertension
Liver cirrhosis, the end-stage of chronic liver fibrosis, 
shows a prevalence of 250 patients per 100000 inhabi­
tants[1,2]. Pathological alterations of liver parenchyma 
and hepatic perfusion lead to a decrease in hepatocyte 
function and an increase in transhepatic perfusion 
resistance, resulting in portal hypertension. Over time, 
up to 20% of cirrhotic patients develop a hepatocellular 
carcinoma[1].
Causes of liver cirrhosis are manifold (Table 1). In 
Europe and the United States, alcoholic liver disease 
is the predominant cause of hepatic cirrhosis, followed 
by chronic viral hepatitis (B/C) and nonalcoholic fatty 
liver disease. In many African and Asian countries, 
chronic viral hepatitis remains the main cause of liver 
cirrhosis[1].
Phenotypically, liver cirrhosis can show a variety 
of symptoms from almost asymptomatic stage to 
liver failure. In advanced cirrhosis, live­threatening 
complications are bleeding from esophageal varices, 
hydroptic decompensation (ascites), spontaneous 
bacterial peritonitis and hepatic encephalopathy. A 
first evaluation of the cirrhotic stage can be estimated 
by the Child­Pugh­Turcotte Score (CPT) using the 
INR (International Normalized Ratio), the serum 
bilirubine, the serum albumine, the grade of hepatic 
encephalopathy and the grade of ascites[3]. Although 
the CPT score is a valuable method to categorize 
patients into individuals with compensated (CPT A), 
mildly (CPT B) or severely decompensated (CPT 
C) cirrhosis, it can be influenced by the subjective 
assessment of the parameters “ascites” and “ence­
phalopathy”. Furthermore, it does not include the 
prognostic relevant assessment of renal function. 
Another system evaluating the mortality of a 
patient with liver cirrhosis is the Model of End Stage 
Liver Disease (MELD) score, currently used for organ 
allocation in liver transplantation[4,5]. It is reproducibly 
calculated from creatinine, bilirubin and INR, and does 
not include less precise parameter such as ascites 
or varices. Since a continuous deterioration of each 
pressure (FHVP) in the right hepatic vein as well as the 
wedge hepatic venous pressure (WHVP) at the same 
location[8]. HVPG is then defined as the difference 
of WHVP and FHVP. Since this invasive method may 
not be available everywhere and might also cause 
complications, translational studies are currently 
performed to establish ultrasound­based elastography 
for assessing the degree of portal hypertension. So 
far some promising progress has been made using 
Fibroscan® measurements. Here, a cut­off value of 
13.6 kPa has been described as being 90% sensitive 
to detect clinically relevant portal hypertension, with 
excellent specificity at a higher cut­off value of 21.1 
kPa. Thus, invasive HVPG measurements to diagnose 
clinically relevant portal hypertension may be limited 
to patients without esophageal varices and with a 
Fibroscan® measurement result between 13.0 and 21.1 
kPa[9]. Ongoing clinical assessments will further refine 
this technique[10,11]. Meanwhile, surrogate markers 
such as thrombocytopenia < 100/nL, splenomegaly 
> 12 cm, the endoscopic confirmation of esophageal 
varices (that do not occur in HVPG < 10 mmHg[12]), 
clinical signs of collateralization such as the presence 
of caput medusae and presence as well as extent of 
ascites are used to define portal hypertension[13]. 
PReOPeRaTIve DIagNOsTICs
While taking the medical history of a patient with liver 
cirrhosis, a main focus should lie on prior episodes 
of decompensation or variceal hemorrhage, ongoing 
alcohol abuse and further comorbidities such as 
congestive gastropathy, cardiovascular complaints 
(coronary artery sclerosis, cirrhotic cardiomyopathy), 
pulmonary disorders (chronic obstructive pulmonary 
disease (COPD), hepato­pulmonary syndrome, pleural 
effusion), restricted renal function (hepato­renal 
syndrome), diabetes and malnutrition[14,15]. During 
physical examination, signs of portal hypertension 
such as ascites and caput medusae may be seen. 
Preoperative laboratory screening should include a full 
blood count (anemia, thrombocytopenia), coagulation 
tests (INR), renal function parameters (creatinine, 
GFR, electrolytes) as well as liver function parameters. 
Radiologic examinations should consist of (if possible: 
contrast­enhanced) ultrasound (parenchymal liver 
morphology, focal lesions, liver perfusion, umbilical 
vein recanalization, elastography if available) and 
contrast­enhanced CT/MRI scans (morphology of 
lesions indicating liver resection, staging, morphology 
of collaterals, volumetric assessment of remnant liver). 
Several methods have been established to spe­
cifically evaluate the liver function prior to hepatic 
resections[16]. Among them, the LiMaX (maximum 
liver function capacity) test, which analyses the 
liver­specific, cytochrome P450­based metabolism 
of 13C­methacetin[17,18], and the Indocyanine­green­
Clearance (ICG­Clearance) test[19-21] are most commonly 
used. Ishizawa et al[22] have reported the combination 
of ascites, bilirubine and indocyanine­green­clearance to 
be excellent predictors of resectability for hepatocellular 
carcinoma (HCC) independent of portal hypertension. 
However, LiMaX­Test and Indocyanine­green­clearance 
both analyse the global liver function and cannot 
distinguish the expected post­surgical liver remnant 
function. A method that may distinguish this remnant 
liver function is functional scintigraphy and functional 
MRI using Gd­EOP­DTPA contrast enhancement[23­25]. 
Nonetheless, up until today, little experience of these 
assays in patients with liver cirrhosis and portal 
hypertension exists and future prospective studies are 
warranted.
A critical issue is the remaining liver remnant after 
resection. In general, CT­based volumetric assessment 
is used to estimate the volume of liver that remains 
after resection. Upon liver cirrhosis, a minimum of 
40% well-perfused liver tissue must remain in situ to 
maintain an adequate function[26]. However, this is not 
an absolute value and should be taken with caution. 
PReOPeRaTIve RIsk evalUaTION
Since liver cirrhosis and portal hypertension significantly 
increase perioperative morbidity and mortality[27,28], a 
thorough pre­operative risk evaluation is recommended. 
The American Society of Anaesthesiologists Score 
(ASA-Score), although not originally meant specifically 
for liver surgery, has been shown to reliably predict 7­d 
mortality of patients with liver cirrhosis after abdominal 
surgery[28]. In addition, CPT and MELD score are used 
to predict the mortality after major abdominal surgery. 
Thus, mortality rates of 10%, 30% and 80% were 
observed for patients classified as CPT A, CPT B and 
CPT C, respectively[29,30]. However, recent improvements 
in surgical technique and perioperative management 
have significantly reduced mortality especially in CPT 
A and CPT B patients[12,22,29-33]. The impact of portal 
hypertension on perioperative morbidity and long­
term survival has lately been discussed controversially. 
Berzigotti et al[12] have shown a relative risk of 2.0 
for 3­ and 5­year mortality and a relative risk of 3.0 
for perioperative clinical cirrhotic decompensation in 
patients undergoing liver resection for HCC with and 
without portal hypertension. Similar results were shown 
for subgroups of patients undergoing resection of a 
single small HCC in CPT A cirrhosis. In contrast, other 
reports state that portal hypertension is no prognostic 
parameter for perioperative mortality and long­term 
survival in multivariate analyses[34]. A matched­pair 
analysis of 241 cirrhotic patients undergoing liver 
resections for HCC showed no significant difference in 
perioperative morbidity and long­term postoperative 
outcome in patients with or without portal hypertension 
and identified the MELD-score and the extent of liver 
surgery as only specific prognostic parameters[34]. Using 
the MELD score as predictor, mortality after abdominal 
surgery has been described to be 5%-10% for MELD 
≤ 11, 25%-54% for MELD 12%-25% and 55%-80% 
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indications for hepatic surgery in these high­risk 
patients.
According to the European Association for the 
Study of the Liver (EASL) and American Association 
for the Study of the Liver (AASLD) guidelines for HCC 
therapy, surgical resections are restricted to patients 
without portal hypertension, patients showing a 
normal bilirubin level and a singular tumor nodule[12]. 
In addition, the Barcelona Clinic Liver Cancer (BCLC) 
classification recommends curative liver resections for 
HCC in cirrhotic patients only in early tumor stages and 
in CPT A cirrhosis without portal hypertension[41]. In 
contrast, several studies world­wide have shown that 
HCC resections can be performed in cirrhotic patients 
with portal hypertension showing acceptable mortality 
rates with clear oncologic benefits[22,33,34]. Furthermore, 
Torzilli et al[42] could show that in centres specialized 
in complex liver surgery, 50% of patients undergoing 
liver resection in cirrhosis are resected outside the 
BCLC criteria with 5­year overall survival rates of 
57% and 38% for BCLC B and BCLC C patients, 
respectively. Several authors could show that hepatic 
resections in patients diagnosed with HCC in advanced 
cirrhosis result in significantly better long-term survival 
compared to transarterial chemoembolization[43­46] 
and that tumor size alone should not be an exclusion 
criteria for curative surgery[47]. In a randomized 
controlled clinical trial, Yin et al[46] performed liver 
resections or transarterial chemoembolizations in 173 
HCC patients exceeding the Milan criteria. The authors 
described a significantly better long­term survival in 
patients undergoing liver resection (3­year overall 
survical rate 51.5% vs 18.1%). Thus, advanced 
liver cirrhosis and portal hypertension should not 
be considered as absolute contraindication in liver 
resections but must be evaluated individually for each 
patient in the context of the hepatic resection planned 
and further comorbidities of the patient.
Extent of resection
In a cirrhotic liver, a minimum of 40% well-perfused 
liver­volume must remain in situ after resection[26]. 
However, in our institution these radical resections of 
up to 60% liver volume are restricted to CPT A, MELD 
for MELD ≥ 26[35­37]. Furthermore, a study analysing 
liver resections in cirrhotic patients and showing an 
overall-mortality of 16%, defined a MELD score of 9 
as “cut­off” point: none of the patients with less than 
9 points died in the perioperative period whereas a 
29% mortality rate was observed in patients with 9 
or more points[32]. Based on these analyses, the Mayo 
Clinic offers a web­based risk evaluation of 7­, 30­, 
90-, 360- and 1800-d mortality for cirrhotic patients 
after abdominal, cardiac and orthopedic surgery (http://
www.mayoclinic.org/meld/mayomodel9.html)[28]. A 
synopsis of preoperative risk scores is shown in Table 
3. In conclusion, elective abdominal surgery in CPT C 
patients or patients with a MELD > 15 is only feasible 
with significantly increased morbidity and mortality. 
In these patients, potential therapeutic alternatives as 
well as morbidity and mortality in case of conservative 
therapy have to be carefully assessed and risks vs 
potential benefits evaluated for each individual patient. 
In CPT A and MELD < 9 patients, elective surgery 
including liver resections can be performed with 
adequate risk-to benefit ratio. Patients showing a CPT 
B classification and a MELD score of 9-15, the risk-to 
benefit ratio has to be carefully discussed for and 
with each patient. Of note, portal hypertension is not 
adequately included in all of these staging systems and 
has to be taken into consideration in the context of liver 
resection. In particular, thrombocytopenia as one of the 
features of portal hypertension has been associated 
with a significant increase in postoperative major 
complications, postoperative liver failure and finally 
with a more than 3­times higher 60­d mortality[22,38]. 
HePaTIC ReseCTION IN CIRRHOTIC 
lIveRs aND PORTal HyPeRTeNsION
Indication
The most frequent indication for hepatic resections in 
cirrhotic patients with and without portal hypertension 
is HCC. In addition, cholangiocellular adenocarcinoma 
(CCA) and liver metastases may be reasons for liver 
resection upon cirrhosis although several studies 
indicate that cirrhosis reduces the risk of metastasis 
formation[39,40]. Benign hepatic lesions are very rare 
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Table 3  Preoperative risk stratification models for patients with liver cirrhosis[28-30,35-37]
Score Groups Initial function Mortality assessment Mortality after liver resection
ASA 1-6 Perioperative risk stratification for any 
patient
Predictor of 7-d mortality Not specifically defined
CPT A-C Overall survival in patients with liver 
cirrhosis
A: 10%, B: 30%, C: 80%; 
predictor for 30- and 90-d mortality
A: < 9%, no data for B and C
MELD 0-40 Mortality of TIPS-placement 0-11: 5%-10%, 12%-25: 25%-54%, > 26: 55%-80%; 
predictor for 30- and 90-d mortality
≤ 8: 0%; > 8: 29%
Mayo Mortality after abdominal, orthopedic 
and cardiac surgery
7-, 30-, 90-, 360-, 1800-d mortality Not specifically defined
ASA: American Society of Anaesthesiologists; CPT: Child-Pugh-Turcotte; MELD: Model of End Stage Liver Disease; TIPS: Transjugular portosystemic stent 
shunt.
Hackl C et al . Liver surgery in cirrhosis
< 9 patients with no or only mild portal hypertension 
(Figure 1). Some reports indicate that anatomic 
hepatic resections for HCC show a trend towards 
increased disease­free and overall survival compared 
to non­anatomic resections[48­50] whereas others do 
not see a benefit from anatomic resections[51­53]. 
However, to avoid postoperative liver failure due to 
insufficient liver remnant, we would prefer hepatic 
resections to be as parenchymal­sparing as possible. 
In particular, the latter strategy may enable liver 
resections in patients with advanced cirrhosis (CPT 
B) and with (mild) portal hypertension[54]. Lately, 
local ablation using radiofrequency has been shown 
to be an adequate alternative therapy for small 
malignant hepatic lesions < 2 cm with similar long­
term oncologic outcome as surgical resection but 
significantly reduced peri­interventional morbidity[9]. 
Thus, for patients with small malignant liver lesions 
in cirrhosis and portal hypertension local ablation has 
to be considered as an alternative (and potentially 
better) option (see Figure 2). 
Surgical access
Standard access for cirrhotic as well as non­cirrhotic 
patients in liver surgery is the upper abdomen midline 
incision extended by right­upper quadrant traverse 
laparotomy (“inversed L­shape”). In cases where 
right­posterior segmentectomy has to be performed 
and where clamping of the suprahepatic inferior caval 
vein is not possible through inversed L­shape incision, 
a thoraco­abdominal incision is recommended[55­57]. 
In minor resections, a midline incision may suffice. 
The recanalized umbilical vein must be carefully 
ligated or preserved if possible. First studies have also 
established laparoscopic resections in cirrhotic patients. 
In specialized centres, even extended liver resections 
can be performed in a minimally invasive technique 
with removal of the resected liver using a Pfannenstiel 
incision[58]. 
For parenchymal dissections, all techniques used in 
non­cirrhotic patients can be used in cirrhotic patients 
with or without portal hypertension. “Selective” 
dissection techniques are based on discriminating 
the higher tissue resistance of blood vessels and 
bile ducts compared to liver parenchyma. Selective 
dissection techniques are blunt dissection using a pair 
of scissors and selective application of clips, water jet 
dissection and clips, stapler dissection and ultrasound­
aspiration (CUSAR) and clips[59-64]. In our institution, 
blunt selective dissection by scissors and clips is the 
preferred dissection technique. In any case, care must 
be taken of thorough bleeding control during resection. 
Post­resection application of fibrin glue or collage 
fleece has not shown any benefit on blood loss and 
need for blood transfusions[65].
Pringle manoeuvre
Blood loss and need for blood transfusions have been 
defined as independent predictors of postoperative 
morbidity and mortality[66­68]. In cases of problematic 
blood loss during parenchymal dissection, hilar 
vascular occlusion can be applied (Pringle manoeuvre). 
Of note, the Pringle manoeuvre is not recommended 
in cirrhotic patients but sometimes is necessary 
to avoid extensive blood loss. If needed, collateral 
vessels in the liver hilum should be preserved during 
vascular clamping. If vascular clamping cannot be 
avoided, selective clamping of a hepatic lobe, section 
or segment is recommended to limit ischemic and 
reperfusion damage[55,69]. Moreover, hilar vascular 
occlusion should be performed as short as possible. In 
cases where longer occlusion is needed, intermittent 
occlusion, e.g., intervals of 15 min of ischemia, 
followed by 5 min of reperfusion ­ has shown to be 
tolerated better than continuous clamping[70­74]. Total 
hepatic vascular exclusion, i.e., including occlusion 
of the infra­ and suprahepatic caval vein, should be 
avoided since a significant increase in perioperative 
morbidity and mortality has been observed even in 
non­cirrhotic patients[75]. A setting were total hepatic 
vascular exclusion may be necessary is the resection 
of a hepatocellular carcinoma invading the retrohepatic 
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Figure 1  Patient with hepatocellular carcinoma in macroscopic and 
biopsy proven liver cirrhosis but without signs of portal hypertension 
(CTP A, MELD 8, no varices, no splenomegaly, normal thrombocyte count) 
scheduled for right hepatectomy.
Figure 2  Patient with liver metastases in histological proven liver cir­
rhosis with signs of portal hypertension (splenic diameter 15.3 cm, 
thrombocytopenia 77/nL, hypertensive gastropathy) scheduled for 
radiofrequency ablation.
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caval vein and needing (partial) resection and 
replacement of the retrohepatic caval vein.
Cooperation with anaesthesiology
During hepatic resection, a close cooperation and 
communication with the anaesthetic team is essential. 
Since intrahepatic sinusoidal pressure correlates 
with the pressure in the inferior caval vein, which 
again correlates with the central venous pressure 
(CVP), blood loss during parenchymal dissection can 
be significantly decreased by reducing the CVP to 
approximately 5 mmHg[55,69,76]. Reduction of the CVP 
to lower (even negative) values is not recommended 
due the increased risk of air embolism[55]. Restrictive 
volume management, reduction of tidal volume and 
positive end­expiratory pressure, diuretics and reverse 
Trendelenburg positioning are options to reduce the 
CVP[77]. A surgical method to reduce CVP is partial 
clamping of the infrahepatic caval vein[78]. Finally, in 
case of increased blood loss during hepatic resection, 
a decent management including not only blood 
transfusions but also substitution of non­cellular blood 
components (e.g., fresh frozen plasma, coagulation 
factors) is mandatory. It has been observed that a 
restrictive transfusion policy for cirrhotic patients with 
anemia therapeutically targeted to a Hb between 7-9 
g/dL is associated with a better clinical outcome[79]. 
This should be considered in order to avoid an 
overtransfusion policy that can further increase portal 
pressure as consequence of high hepatic inflow.
Drainage 
Routine placement of drainage systems in hepatic 
resections is controversially discussed. In minor 
resections of non­cirrhotic livers in patients without 
portal hypertension, drainage placement is not 
recommended[80]. In major resections, prophylactic 
drainage placement has been associated with 
increased septic complications and prolonged time 
to discharge[81]. However, other publications show 
a significantly reduced intraabdominal pressure 
for temporary drainage of increased postoperative 
ascites and improved wound healing after drainage 
placement[82,83].
POsTOPeRaTIve MORbIDITy
Compared to liver resections in otherwise healthy 
patients, resections in cirrhotic livers in patients 
with portal hypertension show a markedly increased 
postoperative morbidity of 22%-50%[22,33,34,66].
Liver failure
Postoperative liver failure is the most serious and life­
threatening complication after liver resection. Several 
definitions for “liver failure” have been proposed 
over the last 20 years. So far, the commonly used 
definitions, though initially not developed to score 
liver resections in cirrhotic livers, are the “50­50 crite­
ria”, the International Study Group of Liver Surgery 
(ISGLS)­criteria and the “peakBili > 7” criteria (see 
Table 4)[84­86].
Liver transplantation as only causal therapy of liver 
failure is often no option in these patients. Treatment 
must therefore focus on optimal perfusion of remnant 
liver, adequate infection prophylaxis and intensive care 
management of fluid balance, electrolytes, coagulation 
and kidney function. 
Ascites, infectious complications
Ascites is a major problem after hepatic resections in 
cirrhotic patients with portal hypertension, even if no 
postoperative liver failure occurs. Ascites production 
often suspends after 5­7 d. Supportive therapies 
consist of diuretics (e.g., spironolactone), restrictive 
volume management and substitution of albumin. 
In cases of persisting ascites, a microbiological 
examination is recommended to detect and treat 
infections early. In individual patients, TIPS placement 
(alternatively: splenic artery embolization) must be 
considered.
The rate of infection­associated complications is 
significantly increased after liver resections in cirrhotic 
patients with portal hypertension compared to liver 
resections in otherwise healthy livers[87]. Main foci here 
are pneumonia and superinfected ascites. In suspected 
infection, no delay in antibiotic treatment must be 
made. In cases of superinfected ascites, recommended 
empirical treatment is the use of third generation 
cephalosporins such as ceftriaxone or cefotaxime[88,89], 
alternatively the use of carbapenems[90]. Prior sampling 
and microbiological culture of the ascitic fluid is 
recommended for adequate adaption of the antibiotic 
regime depending on the antimicrobial resistance 
patterns. Control sampling and microbiologic culture of 
the ascitic fluid 48 h after start of antibiotic treatment 
is recommended.
Wound healing and postoperative hemorrhage
Due to the frequently underlying malnutrition and 
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Table 4  Definitions of postoperative liver-failure
Definition Time of scoring
“50-50” bilirubin > 50 µmol/L, prothrombin time 
< 50% (INR > 1.7) → mortality of 50%
POD 5
ISGLS Increased INR and hyperbilirubinemia On or after POD 
5
   ISGLS A No intervention necessary
   ISGLS B Non-invasive intervention necessary
   ISGLS C Invasive intervention necessary
peakBili > 7 Maximum hyperbilirubinemia > 
7 mg/dL any day after surgery - 
predictor for 90-d mortality
Any POD
POD: Postoperative day; ISGLS: International Study Group of Liver 
Surgery.
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postoperative ascites, the rate of wound healing 
disorders in cirrhotic patients is significantly higher 
than in non­cirrhotic patients[91]. Some reports indicate 
that abdominal closure with a running suture pre­
vents wound dehiscence. Moreover, placement of an 
intraabdominal drainage to prevent fluid collection 
and to lower the intraabdominal pressure has been 
proposed although this is discussed controversially (see 
above). 
Postoperative hemorrhage in cirrhotic patients can 
be caused by superficial wound bleeding, bleeding 
from the resection site as well as by GI bleedings. 
Rapid diagnostic assessment and interdisciplinary 
surgical­medical therapy including supplementation of 
coagulation products are essential in these potentially 
life­threatening complications.
Results after liver resection in cirrhosis and portal 
hypertension
A recent analysis of 2046 patients treated in 10 high­
volume centres for liver surgery has shown that 
only 50% of patients were operated within the BCLC 
recommendations, i.e., BCLC stage 0­A and no portal 
hypertension. 36% and 14% of patients underwent 
liver resection in BCLC stage B and C, respectively[42]. 
In this publication, 5­year overall survival rates after 
HCC resections in BCLC A/B/C cirrhosis were 61%, 
57% and 38% and 5-year disease free survival of 21%, 
27% and 18%. Thus, the authors conclude that liver 
resections for HCC can be performed even in higher 
degrees of cirrhosis with acceptable long­term outcome 
and that the BCLC/EASL/AASLD guidelines should 
thus be updated. Furthermore, several publications 
could show that portal hypertension is no prognostic 
factor for long­term survival or HCC recurrence in 
multivariate analyses[25,34]. In contrast, Berzigotti et 
al[12] determined portal hypertension as an independent 
factor for decreased long­term survival and increased 
perioperative decompensation after HCC resection. 
However, since many cirrhotic patients diagnosed with 
HCC do not qualify for liver transplantation, taking an 
increased operative risk must carefully be discussed 
for and with each individual patient in the light of the 
potential long­term oncologic outcome.
sURgICal THeRaPy Of PORTal 
HyPeRTeNsION
Only liver transplantation (LT) is the causal therapy 
for patients diagnosed with portal hypertension 
and advanced liver cirrhosis[92]. However, not all 
cirrhotic patients are candidates for LT. In particular, 
patients suffering from severe complications from 
portal hypertension such as variceal hemorrhage 
and subsequent failure of conservative, endoscopic 
and angiographic interventions are referred to TIPS 
placement[93,94]. Only if TIPS placement is technically not 
feasible, shunt surgery may be considered. Interestingly, 
several studies comparing TIPS and shunt surgery 
show a significantly reduced recurrence of hemorrhage 
and less occlusive complications for shunt surgery[95]. 
However, due to the high perioperative morbidity and 
mortality, shunt surgery should only be considered 
for CPT A or well­compensated CPT B patients[96]. 
Depending on the region of the portal­venous system 
requiring relief of vascular pressure and influenced by 
possible anastomotic sites, several shunting techniques 
have been developed (see Table 5). If possible, only a 
partial bypass of the portalvenous flow is recommended 
to minimize the risk of encephalopathy.
More rarely used shunting techniques are the 
meso­caval side­to­side shunt (+/­ interposition 
graft), the proximal end­to­side splenorenal shunt 
(Linton), the spleno­renal side­to­side shunt (Cooley), 
the coronario­cava­ end­to­side shunt (Inokuchi) and 
the mesenterico­portal Rex­Shunt. Because shunt 
surgery is no longer a common practice, it should only 
be performed where there is sufficient expertise at 
specialized centers.
CONClUsION
In conclusion, hepatic resections in cirrhotic patients 
with portal hypertension show a significantly increased 
mortality and morbidity. However, due to ongoing 
improvements in surgical technique and intensive 
care management, surgery is feasible in selected 
patients with adequate long­term outcome. Patients 
have to be carefully screened for the degree of liver 
cirrhosis (CPT A­C, MELD­score), grade of portal 
hypertension (thrombocyte count, splenomegaly, 
presence of collaterals and varices, elastography, 
HPVG­measurement) and comorbidities. To us, portal 
hypertension is not an absolute contraindication for 
liver resections in cirrhotic patients. A close interaction 
with anaesthesiology and the critical care team is 
mandatory for optimal perioperative management. 
Main indications for liver resections in cirrhotic 
patients are HCC, but also CCA and, rarely, hepatic 
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Table 5  Shunt surgery in portal hypertension and hepatic 
cirrhosis[93,95,96]
Shunt Bypass of 
portal venous 
flow
Recurrent haemorrhage/
complications
Porto-caval; 
end-to-side
Complete Low rate of recurrent haemorrhage 
(< 5%)
Low degree of shunt occlusion
40% encephalopathy
Increase in ascites
Porto-caval, 
side-to-side +/- 
interposition graft
Partial Recurrent haemorrhage 5%
Low degree of shunt occlusion (5%)
5% encephalopathy
Distal splenorenal 
shunt (Warren)
Partial Recurrent haemorrhage 5%-8%
Shunt occlusion 10%
Selective decompression of 
gastroesophageal varices
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metastases. Elective surgery should not only be 
restricted to patients with CPT A cirrhosis, but should 
also be offered to very well selected patients with 
more advanced cirrhosis. During surgery, abdominal 
access should be made carefully to preserve potential 
collaterals. Careful dissection to prevent intraoperative 
blood loss is necessary and the extent of liver resection 
should be restricted to a minimum. Moreover, the 
therapeutic alternative of local ablation (radiofrequency 
ablation, irreversible electroporation among others) 
by an experienced interventional radiologist should 
always be considered. In case of surgery, the Pringle­
manoeuvre should be avoided but may help to bridge 
critical situations. During the postoperative period, 
close interdisciplinary management by the hepatobiliary 
surgical team, critical care specialists and hepatologists 
is warranted for optimized stabilisation of these critical 
patients and for early and appropriate management of 
complications.
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